

## STALLERGENES GREER TO REPORT FIRST HALF FINANCIAL RESULTS ON 29 AUGUST 2018

**London (UK), August 16, 2018** – Stallergenes Greer, a biopharmaceutical company specializing in treatments for respiratory allergies, today announced it will report financial results for the first half of its 2018 fiscal year after the market closes on 29 August 2018. The Company's management will host a live audio webcast of its earnings conference call the following day, 30 August 2018, at 10:30 am London / 11:30am Paris / 5:30 am Boston to discuss the results.

Members of the financial community may access the conference through the dial-in information provided on the company's website at <http://stallergenesgreer.com/financial-calendar-events>. The live audio webcast will be accessible to the general public via the following link: [https://edge.media-server.com/m6/go/STAGR\\_18HY](https://edge.media-server.com/m6/go/STAGR_18HY). Participants are asked to connect at least 15 minutes prior to the conference call to register, download and install any necessary audio software.

### ABOUT STALLERGENES GREER PLC

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the US) and Stallergenes SAS (whose registered office is in France).

### TRADING INFORMATION

Name: Stallergenes Greer  
ISIN: GB00BZ21RF93 1 - Ticker: STAGR  
ICB Classification: 4577  
LEI: 213800CYVZA7GJQEME86  
Market: Euronext Paris regulated market

Additional information is available at <http://www.stallergenesgreer.com>.

This document (including information incorporated by reference in this document), oral statements made and other information published by the Company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe," "expects," "project," "estimated," "forecast," "should," "plan," "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in the Company's 2017 annual report published on 16 April 2018 on the Company's website [www.stallergenesgreer.com](http://www.stallergenesgreer.com). Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.

### CONTACTS

#### Communications and Investor Relations

Natacha Gassenbach  
Tel: +1 (617) 682 2626  
Email: [natacha.gassenbach@stallergenesgreer.com](mailto:natacha.gassenbach@stallergenesgreer.com)

Caitlin Stefanik  
Tel: +1 (857) 331 4117  
Email: [caitlin.stefanik@stallergenesgreer.com](mailto:caitlin.stefanik@stallergenesgreer.com)

#### Media Relations Agency

Havas Paris (Europe)  
Samuel Rousseau  
+33 6 77 88 32 43  
E-mail : [samuel.rousseau@havas.com](mailto:samuel.rousseau@havas.com)

#### Investor Relations Agency

FTI Consulting

Arnaud de Chefontaines

Tel: +33 1 47 03 68 10

Email: [stalleregenesgreer@fticonsulting.com](mailto:stalleregenesgreer@fticonsulting.com)